2025年12月30日,Structure Therapeutics(硕迪生物)通过其子公司Gasherbrum Bio与罗氏和基因泰克达成了一项非独家专利许可协议,并获得了1亿美元的预付款。硕迪生物将授权这两家制药巨头使用特定的口服GLP-1受体激动剂专利,这些专利与硕迪生物的核心候选药物阿利奈普仑(aleniglipron)分属不同品类。根据协议条款,基因泰克需在30天内支付这笔1亿美元的不可...
Source Link2025年12月30日,Structure Therapeutics(硕迪生物)通过其子公司Gasherbrum Bio与罗氏和基因泰克达成了一项非独家专利许可协议,并获得了1亿美元的预付款。硕迪生物将授权这两家制药巨头使用特定的口服GLP-1受体激动剂专利,这些专利与硕迪生物的核心候选药物阿利奈普仑(aleniglipron)分属不同品类。根据协议条款,基因泰克需在30天内支付这笔1亿美元的不可...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.